Obinutuzumab
TTPNetwork are proud to have contributed to this paper.
Obinutuzumab elective therapy to prevent immuneThrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)
https://www.england.nhs.uk/wp-content/uploads/2023/11/2255-obinutuzumab-cc-policy.pdf?fbclid=IwAR0L_BEU4m0x8uRKi2s-f5dbj9WnZEve7yvrlLDFvv25_UvPIvZ2b8hJZKc
